Boyd Mudenda

Therapy of Advanced Non–Small-Cell Lung Cancer With an SN-38-Anti-Trop-2 Drug Conjugate, Sacituzumab Govitecan

Rebecca S. Heist, Michael J. Guarino, Gregory A. Masters et al. · Journal of Clinical Oncology · 2017 · 181 citations

Therapy of Small Cell Lung Cancer (SCLC) with a Topoisomerase-I–inhibiting Antibody–Drug Conjugate (ADC) Targeting Trop-2, Sacituzumab Govitecan

Jhanelle E. Gray, Rebecca S. Heist, Alexander Starodub et al. · Clinical Cancer Research · 2017 · 155 citations · Full text

The relationship between serum p53 autoantibodies and characteristics of human breast cancer

Boyd Mudenda, JA Green, B Green et al. · British Journal of Cancer · 1994 · 91 citations · Full text

Breast Oncology, Medicine, Immunology +7

Glycaemic Control and Associated Self-Management Behaviours in Diabetic Outpatients: A Hospital Based Observation Study in Lusaka, Zambia

Emmanuel Musenge, Charles Michelo, Boyd Mudenda et al. · Journal of Diabetes Research · 2015 · 49 citations · Full text

Randomized phase II study of weekly versus every-3-week ixabepilone plus bevacizumab (ixa/bev) versus paclitaxel plus bev (pac/bev) as first-line therapy for metastatic breast cancer (MBC)

H. S. Rugo, Mario Campone, D. Amadori et al. · Journal of Clinical Oncology · 2009 · 42 citations

First-line Therapy, Metastatic Breast Cancer, Breast Oncology +15